{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:02:17Z","timestamp":1792065737789,"version":"4.4.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP21fk0310112"],"award-info":[{"award-number":["JP21fk0310112"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP21be0304203"],"award-info":[{"award-number":["JP21be0304203"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["25mk0121328"],"award-info":[{"award-number":["25mk0121328"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K14379"],"award-info":[{"award-number":["23K14379"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Pharmacokinetics"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.dmpk.2026.101530","type":"journal-article","created":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T02:24:17Z","timestamp":1772850257000},"page":"101530","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Application of HepaSH cells for predicting cholestatic drug-induced liver injury via bile acid-dependent toxicity assay"],"prefix":"10.1016","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7609-5569","authenticated-orcid":false,"given":"Akinori","family":"Takemura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunya","family":"Naito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Higuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shotaro","family":"Uehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nao","family":"Yoneda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3706-2454","authenticated-orcid":false,"given":"Hiroshi","family":"Suemizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7187-9639","authenticated-orcid":false,"given":"Kousei","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dmpk.2026.101530_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1872-034X.2008.00400.x","article-title":"Recent status of drug-induced liver injury","volume":"39","author":"Takikawa","year":"2009","journal-title":"Hepatol Res"},{"key":"10.1016\/j.dmpk.2026.101530_bib2","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1124\/dmd.111.040758","article-title":"In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans","volume":"40","author":"Dawson","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2026.101530_bib3","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/toxsci\/kfx284","article-title":"Measures of BSEP inhibition in vitro are not useful predictors of DILI","volume":"162","author":"Chan","year":"2018","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.dmpk.2026.101530_bib4","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1007\/s00204-025-04016-0","article-title":"Cell-based approaches for the mechanistic understanding of drug-induced cholestatic liver injury","volume":"99","author":"Timor-L\u00f3pez","year":"2025","journal-title":"Arch Toxicol"},{"key":"10.1016\/j.dmpk.2026.101530_bib5","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/toxsci\/kft176","article-title":"A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development","volume":"136","author":"Morgan","year":"2013","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.dmpk.2026.101530_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2020.114958","article-title":"Mechanism-based integrated assay systems for the prediction of drug-induced liver injury","volume":"394","author":"Kawaguchi","year":"2020","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.dmpk.2026.101530_bib7","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/j.tiv.2015.06.004","article-title":"Basal efflux of bile acids contributes to drug-induced bile acid-dependent hepatocyte toxicity in rat sandwich-cultured hepatocytes","volume":"29","author":"Susukida","year":"2015","journal-title":"Toxicol Vitro"},{"key":"10.1016\/j.dmpk.2026.101530_bib8","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/toxsci\/kfx091","article-title":"Troglitazone inhibits bile acid amidation: a possible risk factor for liver injury","volume":"158","author":"Ogimura","year":"2017","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.dmpk.2026.101530_bib9","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1016\/j.xphs.2017.04.050","article-title":"Metabolic activation of cholestatic drug-induced bile acid-dependent toxicity in human sandwich-cultured hepatocytes","volume":"106","author":"Ogimura","year":"2017","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.dmpk.2026.101530_bib10","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1124\/dmd.115.065425","article-title":"Prediction of the clinical risk of drug-induced cholestatic liver injury using an in vitro sandwich cultured Hepatocyte assay","volume":"43","author":"Susukida","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2026.101530_bib11","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/j.xphs.2016.01.013","article-title":"Establishment of a Drug-Induced, bile acid-dependent hepatotoxicity model using HepaRG cells","volume":"105","author":"Susukida","year":"2016","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.dmpk.2026.101530_bib12","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.dmpk.2019.04.004","article-title":"In vitro bile acid-dependent hepatocyte toxicity assay system using human induced pluripotent stem cell-derived hepatocytes: current status and disadvantages to overcome","volume":"34","author":"Sakai","year":"2019","journal-title":"Drug Metabol Pharmacokinet"},{"key":"10.1016\/j.dmpk.2026.101530_bib13","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.bbrc.2023.04.054","article-title":"HepaSH cells: experimental human hepatocytes with lesser inter-individual variation and more sustainable availability than primary human hepatocytes","volume":"663","author":"Uehara","year":"2023","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.dmpk.2026.101530_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmd.2025.100202","article-title":"Prediction of human hepatic clearance with HepaSH monolayers for low-turnover compounds","author":"Uehara","year":"2025","journal-title":"Drug Metabol Dispos"},{"key":"10.1016\/j.dmpk.2026.101530_bib15","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1124\/jpet.106.119073","article-title":"Differential inhibition of rat and human Na+-dependent taurocholate cotransporting polypeptide (NTCP\/SLC10A1)by bosentan: a mechanism for species differences in hepatotoxicity","volume":"321","author":"Leslie","year":"2007","journal-title":"J Pharmacol Exp Therapeut"},{"key":"10.1016\/j.dmpk.2026.101530_bib16","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.bbalip.2005.10.006","article-title":"Transport by vesicles of glycine- and taurine-conjugated bile salts and taurolithocholate 3-sulfate: a comparison of human BSEP with rat Bsep","volume":"1738","author":"Hayashi","year":"2005","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.dmpk.2026.101530_bib17","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2131\/jts.50.379","article-title":"Alteration of bile acid composition is a possible risk factor for antibiotics-induced liver injury","volume":"50","author":"Takemura","year":"2025","journal-title":"J Toxicol Sci"},{"key":"10.1016\/j.dmpk.2026.101530_bib18","doi-asserted-by":"crossref","DOI":"10.1038\/srep38694","article-title":"Functional human induced hepatocytes (hiHeps) with bile acid synthesis and transport capacities: a novel in vitro cholestatic model","volume":"6","author":"Ni","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.dmpk.2026.101530_bib19","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/978-1-0716-2557-6_8","article-title":"In vitro assay system to detect drug-induced bile acid-dependent cytotoxicity using hepatocytes","volume":"2544","author":"Takemura","year":"2022","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.dmpk.2026.101530_bib20","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1016\/j.xphs.2017.05.017","article-title":"Identification of bile acids responsible for inhibiting the bile salt export pump, leading to bile acid accumulation and cell toxicity in rat hepatocytes","volume":"106","author":"Oizumi","year":"2017","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.dmpk.2026.101530_bib21","doi-asserted-by":"crossref","first-page":"3920","DOI":"10.1016\/j.jchromb.2009.09.038","article-title":"Rapid quantification of bile acids and their conjugates in serum by liquid chromatography-tandem mass spectrometry","volume":"877","author":"Scherer","year":"2009","journal-title":"J Chromatogr, B: Anal Technol Biomed Life Sci"},{"key":"10.1016\/j.dmpk.2026.101530_bib22","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.cgh.2020.06.067","article-title":"A high serum level of taurocholic acid is correlated with the severity and resolution of drug-induced liver injury","volume":"19","author":"Tian","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dmpk.2026.101530_bib23","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0925-4439(95)00066-D","article-title":"Inhibition of bile acid conjugation by cyclosporin A","volume":"1272","author":"Vessey","year":"1995","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.dmpk.2026.101530_bib24","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1152\/physiol.00020.2008","article-title":"The role of FXR in disorders of bile acid homeostasis","volume":"23","author":"Eloranta","year":"2008","journal-title":"Physiology"},{"key":"10.1016\/j.dmpk.2026.101530_bib25","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1007\/s00204-020-02804-4","article-title":"In vitro assessment of farnesoid X receptor antagonism to predict drug-induced liver injury risk","volume":"94","author":"Norona","year":"2020","journal-title":"Arch Toxicol"},{"key":"10.1016\/j.dmpk.2026.101530_bib26","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1089\/aivt.2018.0011","article-title":"Cholestatic drug induced liver injury: a function of bile salt export pump inhibition and farnesoid X receptor antagonism","volume":"4","author":"Jackson","year":"2018","journal-title":"Applied In Vitro Toxicology"},{"key":"10.1016\/j.dmpk.2026.101530_bib27","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1248\/bpb.30.739","article-title":"Involvement of bile salt export pump in flutamide-induced cholestatic hepatitis","volume":"30","author":"Iwanaga","year":"2007","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.dmpk.2026.101530_bib28","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1124\/dmd.105.008623","article-title":"Detection of a new N-oxidized metabolite of flutamide, N-[4-nitro-3-(trifluoromethyl)phenyl]hydroxylamine, in human liver microsomes and urine of prostate cancer patients","volume":"34","author":"Goda","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2026.101530_bib29","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.3390\/ijms26073332","article-title":"Gut microbiota and its metabolite Taurine-\u03b2-Muricholic acid contribute to Antimony- and\/or copper-induced liver inflammation","volume":"26","author":"Wu","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.dmpk.2026.101530_bib30","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1194\/jlr.RA119000395","article-title":"Regulation of bile acid metabolism in mouse models with hydrophobic bile acid composition","volume":"61","author":"Honda","year":"2020","journal-title":"J Lipid Res"},{"key":"10.1016\/j.dmpk.2026.101530_bib31","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.bbadis.2018.05.011","article-title":"Animal models to study bile acid metabolism","volume":"1865","author":"Li","year":"2019","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"10.1016\/j.dmpk.2026.101530_bib32","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1124\/dmd.117.077420","article-title":"Progressive and preferential cellular accumulation of hydrophobic bile acids induced by cholestatic drugs is associated with inhibition of their amidation and sulfation","volume":"45","author":"Sharanek","year":"2017","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2026.101530_bib33","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1002\/hep.27206","article-title":"Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump","volume":"60","author":"Aleo","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.dmpk.2026.101530_bib34","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/toxsci\/57.1.177","article-title":"Bile acids affect liver mitochondrial bioenergetics: possible relevance for cholestasis therapy","volume":"57","author":"Rolo","year":"2000","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.dmpk.2026.101530_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.tiv.2020.104785","article-title":"Successful energy shift from glycolysis to mitochondrial oxidative phosphorylation in freshly isolated hepatocytes from humanized mice liver","volume":"65","author":"Ikeyama","year":"2020","journal-title":"Toxicol Vitro"}],"container-title":["Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436726000169?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436726000169?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T02:52:00Z","timestamp":1785898320000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347436726000169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":35,"alternative-id":["S1347436726000169"],"URL":"https:\/\/doi.org\/10.1016\/j.dmpk.2026.101530","relation":{},"ISSN":["1347-4367"],"issn-type":[{"value":"1347-4367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Application of HepaSH cells for predicting cholestatic drug-induced liver injury via bile acid-dependent toxicity assay","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Pharmacokinetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmpk.2026.101530","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101530"}}